David M. Aafedt is quoted in MedCity News
about the landmark settlement that the Department of Justice reached with GlaxoSmithKline on Monday, July 2, 2012. “The settlement is pretty remarkable in the sense that it shows how far companies are willing to go to sell their products in this extraordinarily competitive environment and the lengths that the government will go to punish the fraud and abuse on the system,” said David Aafedt, shareholder with Winthrop & Weinstine, a Minneapolis law firm that represents medical device makers, pharma companies and providers.
“This aggressive fraud and abuse enforcement is going to be one of the legacies of the Obama administration, whether it concludes this upcoming January or in 2017,” Aafedt said. “I think he has set a very high standard against which the future administrations will be gauged.”
According to MedCity News
, the trend is only expected to continue with last week’s U.S. Supreme Court ruling that upheld the Affordable Care Act. "That’s because the law set aside $350 million to combat fraud, which means new investigators and agents can be hired," Aafedt said. The ACA also encourages better data sharing among federal agencies and at the state level as well as expanded overpayment recovery efforts related to Medicare and Medicaid, among other things. “So you can expect to see the DOJ and the HHS’s Office of Inspector General to continue to fight these sorts of claims quite vigorously,” Aafedt said.
To see the full article, click here
Parmar, Arundhati. Attorney: "GSK settlement shows fighting healthcare fraud will be legacy of Obama’s tenure" MedCity News
3 July 2012.